Ribavirin

AdipoGen Life Sciences
Product Code: AG-CR1-3719
Product Group: Other Biochemicals
CodeSizePrice
AG-CR1-3719-M05050 mg£30.00
Quantity:
AG-CR1-3719-M250250 mg£60.00
Quantity:
AG-CR1-3719-G0011 g£100.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
NSC 163039; Rebetol; Ribasphere; Virazole; Copegus; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Appearance:
White to off-white solid.
CAS:
36791-04-5
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Handling Advice:
Keep cool and dry.
Hazards:
H360
InChi:
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChiKey:
IWUCXVSUMQZMFG-AFCXAGJDSA-N
Long Description:
Chemical. CAS: 36791-04-5. Formula: C8H12N4O5. MW: 244.2. Ribavirin is a guanosine analog with broad-spectrum antiviral properties against DNA and RNA viruses, including coronavirus SARS, respiratory syncytial virus, several hemorrhagic fever viruses, hepatitis C (HCV) and influenza. It is also tested for SARS-CoV-2. It acts as a prodrug that can be activated by either mono- or tri-phosphorylation by cellular kinases. These phosphorylated derivatives of ribavirin have diverse effects on both cellular and viral enzymes, resulting in suppression of viral replication and propagation. There are 3 direct mechanisms of action, i) by inhibition of the viral RNA dependent RNA polymerase (RdRp) and RNA synthesis through direct interaction with ribavirin-5'-triphosphate, ii) by interfering with RNA capping activity, and iii) by increasing viral mutation rates through the misincorporation of RBV into the genome. In addition there are also 2 proposed indirect mechanisms, iv) inhibition of inosine monophosphate dehydrogenase (IMPDH) by ribavirin-5'-monophosphate, which leads to the depletion of intracellular GTP pools, v) unphosphorylated Ribavirin has immunomodulatory effects on antiviral cellular responses, enhancing the T-helper type 1 over type 2 responses or upregulating the interferon-stimulated response element. Ribavirin shows anticancer properties. The principal target in several cancers is the oncogenic eukaryotic translation initiation factor 4E (eIF4E), modulated via direct binding and competitive inhibition. Ribavirin has been shown to bind eIF4E at the functional site used to bind the m7G cap of mRNA transcripts in vitro. It competes with target mRNAs for binding, subsequent translocation to the cytoplasm and ultimately translation. Other studies also demonstrate modulation of several other key pathways including ERK, EZH2 and IMPDH.
MDL:
MFCD00058564
Molecular Formula:
C8H12N4O5
Molecular Weight:
244.2
Package Type:
Vial
Precautions:
P308 + P313
Product Description:
Ribavirin is a guanosine analog with broad-spectrum antiviral properties against DNA and RNA viruses, including coronavirus SARS, respiratory syncytial virus, several hemorrhagic fever viruses, hepatitis C (HCV) and influenza. It is also tested for SARS-CoV-2. It acts as a prodrug that can be activated by either mono- or tri-phosphorylation by cellular kinases. These phosphorylated derivatives of ribavirin have diverse effects on both cellular and viral enzymes, resulting in suppression of viral replication and propagation. There are 3 direct mechanisms of action, i) by inhibition of the viral RNA dependent RNA polymerase (RdRp) and RNA synthesis through direct interaction with ribavirin-5'-triphosphate, ii) by interfering with RNA capping activity, and iii) by increasing viral mutation rates through the misincorporation of RBV into the genome. In addition there are also 2 proposed indirect mechanisms, iv) inhibition of inosine monophosphate dehydrogenase (IMPDH) by ribavirin-5'-monophosphate, which leads to the depletion of intracellular GTP pools, v) unphosphorylated Ribavirin has immunomodulatory effects on antiviral cellular responses, enhancing the T-helper type 1 over type 2 responses or upregulating the interferon-stimulated response element. Ribavirin shows anticancer properties. The principal target in several cancers is the oncogenic eukaryotic translation initiation factor 4E (eIF4E), modulated via direct binding and competitive inhibition. Ribavirin has been shown to bind eIF4E at the functional site used to bind the m7G cap of mRNA transcripts in vitro. It competes with target mRNAs for binding, subsequent translocation to the cytoplasm and ultimately translation. Other studies also demonstrate modulation of several other key pathways including ERK, EZH2 and IMPDH.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
O[C@@H]1[C@@H](CO)O[C@@H](N2N=C(C(N)=O)N=C2)[C@@H]1O
Solubility Chemicals:
Soluble in DMSO (15mg/ml) or DMF (15mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Ribavirin: an antiviral agent: R.W. Sidwell, et al.; Pharmacol. Ther. 6, 123 (1979) (Review) | The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase: C.E. Cameron & C. Castro; Curr. Opin. Infect. Dis. 14, 757 (2001) (Review) | Ribavirin in the treatment of severe acute respiratory syndrome (SARS): M.G. van Vonderen, et al.; Neth. J. Med. 61, 238 (2003) (Review) | Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap: A. Kentsis, et al.; PNAS 101, 18105 (2004) | Mechanisms of action of ribavirin against distinct viruses: J.D. Graci & C.E. Cameron; Rev. Med. Virol. 16, 37 (2006) (Review) | Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance: S. Beaucourt & M. Vignuzzi; Curr. Opin. Virol. 8, 10 (2014) (Review) | The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral? J. Casaos, et al.; Mol. Cancer Ther. 18, 1185 (2019) (Review) | Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19: J.S. Khalili, et al.; J. Med. Virol. (Epub ahead of print) (2020) (Review) | Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study: A.A. Elfiky; Life Sci. 25, 117592 (2020)